Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFOCOS: Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients
NCT07610733Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jun 2026
- Primary completion
- Sep 2027
01
Overview
Phase 2, randomised, open-label trial in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Proportion of Participants with E2 <30 pg/mL at 3 months. Planned start Jun 2026; status: not yet recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07610733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07610733.